Trial Profile

Safety and efficacy of Selumetinib in Korean patients with neurofibromatosis type 1 and plexiform neurofibromas

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selumetinib (Primary)
Indications Neurofibromatosis 1; Plexiform neurofibroma
Focus Adverse reactions; Pharmacokinetics
Acronyms ESR-17-12847

Most Recent Events

05 Dec 2024 Results (n=89 ) assessing safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma were published in the Neuro-Oncology.
10 Dec 2020 Planned number of patients changed from 30 to 50.
10 Dec 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com